Newsletter

Sysen 1653 Vodka

Total Labels 1
Approved 1
Expired 0

Gristmill Distillers, Inc. — Keene, NY

New York

About Sysen 1653 Vodka

Sysen 1653 Vodka is a vodka product originating from New York. According to TTB records, the spirit is classified as vodka and carries an alcohol proof designation within the 80 to 89 proof range. The brand maintains one distinct product offering currently tracked in the vodka marketplace. The TTB label approval registry shows one total approval on record for this brand, with 2026 noted as the approval year. Sysen 1653 Vodka represents a vodka entry in the spirits market, with its classification and proof level placing it within standard vodka specifications. The brand's New York origin reflects its connection to a state with a notable spirits production presence. As a vodka category spirit, the product adheres to the regulatory standards and definitions governing this classification under federal spirits regulations. The single product configuration and associated labeling approvals indicate the brand's current market positioning. Information regarding the vodka is limited to the official TTB COLA registry data, which provides the foundational details about the product's classification, origin, and regulatory status within the United States spirits market.

Filter by:
Displaying 1 results
Label Name Spirit Type Status Approval Date Producer
Vodka 80-89 Proof
Sysen 1653 Vodka

VODKA 80-89 PROOF

Vodka 80-89 Proof Approved 2026-02-24 Gristmill Distillers, Inc.

Page 1 of 1

1

Sysen 1653 Vodka at a Glance

Sysen 1653 Vodka has 1 distinct product with 1 total TTB label approvals, including Vodka 80-89 Proof. Labels approved between 2026-02-24 and 2026-02-24. Produced in New York.

All information sourced from public TTB records.

Are you the owner or distributor of Sysen 1653 Vodka?

Claim this brand listing to update information or get featured. Contact [email protected].

Produced At

Gristmill Distillers, INC.

Related Brands

Related Questions

Browse All Labels

Stay informed

Newsletter coming soon.

Follow us on X for new approvals, launches, and industry intelligence.